Stock Financial Ratios, Dividends, Split History
HBANO / Huntington Bancshares, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||29,043.34|
|Enterprise Value ($M)||37,795.34|
|Book Value ($M)||11,308.00|
|Book Value / Share||10.26|
|Price / Book||2.57|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Common Stock Shares Outstanding||1,072,026,681|
|Common Shares Outstanding||1,072,026,681|
|Weighted Average Number Of Shares Outstanding Basic||1,084,686,000|
|Preferred Stock Shares Outstanding||1,098,006|
|Weighted Average Number Diluted Shares Outstanding Adjustment||51,500,000|
|Weighted Average Number Of Diluted Shares Outstanding||1,136,186,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.06|
|Return on Assets (ROA)||0.01|
|Return on Equity (ROE)||0.12|
|Identifiers and Descriptors|
|Central Index Key (CIK)||49196|
|SIC 6021 - National Commercial Banks|
Stock splits are used by Huntington Bancshares, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
While the bank is profitable, loan earnings have come under pressure with the flattening of the yield curve. (4-0)
Chicago, IL – July 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include M&T Bank Corp. (MTB - Free Report) , Customers Bancorp, Inc. (CUBI - Free Report) , Metropolitan Bank Holding Corp. (MCB - Free Report) and Triumph Bancorp, Inc. (25-0)
While banks are gearing up for the Q2 earnings season, the Federal Reserve has given clean bills of health to majority of the large American banks. Strong jobs numbers, in fact, raised the possibility of further rate hikes which bodes well for banks. (19-0)
Discover Financial Services (DFS - Free Report) recently announced that it has been notified by the Board of Governors of the Federal Reserve System that the regulatory body has no objections to the company’s capital actions through Jun 30, 2019. Per the company’s capital plan, it would increase its next quarterly dividend from 35 cents to 40 cents per share of common stock. During the four quarters ending Jun 30, 2019, it has also approved a share repurchase of up to $1. (46-0)
One sector that was absolutely demolished in the most recent quarter was the financials, and with second-quarter earnings right around the corner, there could be some very positive tailwinds for the sector as we start the third quarter. With the market seemingly in a very precarious position, despite the fact that the economy looks to be in the best shape in years, banks may be an outstanding buy. (45-0)
as of ET